Catinazzo Thomas sold $3.2M of RLAY
Catinazzo Thomas (Chief Financial Officer) sold 187,163 shares of Relay Therapeutics, Inc. (RLAY) at an average of $16.97 ($16.97–$17.01, $3.18M total) across 4 trades on 2026-06-22 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosure provides a concrete datapoint on insider selling activity by the CFO, but it does not include new guidance, trial results, contracts, or regulatory actions.
Market read
Traders may monitor insider activity for sentiment, but the 10b5-1 framing suggests limited incremental information about near-term fundamentals.
What to watch
The filing does not disclose reasons for the sale, and the net effect depends on whether other insiders or large holders are simultaneously buying or selling.
Background
The article is an SEC Form 4 insider transaction disclosure for Relay Therapeutics, Inc.
Ticker impact
Relay Therapeutics CFO Thomas Catinazzo sold about 187,163 shares in open-market trades for roughly $3.18M under a 10b5-1 plan.
Likely limited, short-lived sentiment impact; no direct signal on company fundamentals from the filing alone.
The filing is a Form 4 insider transaction with a stated 10b5-1 pre-arranged plan, which typically reduces interpretive weight versus discretionary selling.
Market effects
Minimal; this is company-specific insider activity with no sector-wide regulatory or operational change.
None indicated.
None indicated.
Counterpoint
Because the sale is under a pre-arranged 10b5-1 plan, it may reflect routine liquidity planning rather than bearish expectations.
Key entities
- issuerRelay Therapeutics, Inc.
Subject of the Form 4 insider transaction disclosure.
- insiderThomas Catinazzo
Chief Financial Officer who executed open-market sales under a 10b5-1 plan.
